| Date Filed | Type | Description |
| 10/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/10/2023 |
SC 13G/A
| FIL Ltd reports a 5.4% stake in SYNLOGIC INC |
| 10/06/2023 |
3
| New Enterprise Associates 14, L.P. (10% Owner) has filed a Form 3 on SYNLOGIC, INC. |
| 10/04/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 4.7% stake in Synlogic, Inc. |
| 10/02/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 09/29/2023 |
8-K
| Quarterly results |
| 09/29/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/28/2023 |
S-1MEF
| Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]: |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 09/26/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/16/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update - Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU - Cambridge, Mass. August 10, 2023 – Synlogic, Inc. , a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the second quarter ended June 30, 2023, and provided an update on its pipeline programs. “With our pivotal Phase 3 study, Synpheny-3, now underway, we are focused on trial execution and ensuring access, inclusion and an optimal experience for the patients who participate in this landmark ..." |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
4
| Brennan Aoife (See Remarks) has filed a Form 4 on SYNLOGIC, INC.|
Txns:
| Sold 19,042 shares
@ $0.5758, valued at
$11k
|
|
| 04/05/2023 |
4
| Awad Antoine (COO) has filed a Form 4 on SYNLOGIC, INC.|
Txns:
| Sold 6,438 shares
@ $0.5758, valued at
$3.7k
|
|
| 04/05/2023 |
4
| JENSEN MICHAEL VANGSTED (CFO) has filed a Form 4 on SYNLOGIC, INC.|
Txns:
| Sold 2,553 shares
@ $0.5758, valued at
$1.5k
|
|
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Synlogic, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in SYNLOGIC INC |
| 01/20/2023 |
SC 13G/A
| Kryzanowski John A reports a 6.3% stake in Synlogic, Inc. |
| 01/20/2023 |
SC 13G
| Kryzanowski John A reports a 5.3% stake in Synlogic, Inc. |
| 01/19/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|